Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Other Accumulated Expenses: 2014-2019

Historic Other Accumulated Expenses for Viridian Therapeutics, Inc.\DE (VRDN) over the last 3 years, with Mar 2019 value amounting to $113,000.

  • Viridian Therapeutics, Inc.\DE's Other Accumulated Expenses was N/A to $113,000 in Q1 2019 from the same period last year, while for Mar 2019 it was $113,000, marking a year-over-year change of. This contributed to the annual value of $174,000 for FY2018, which is N/A change from last year.
  • Viridian Therapeutics, Inc.\DE's Other Accumulated Expenses amounted to $113,000 in Q1 2019, which was down 35.06% from $174,000 recorded in Q4 2018.
  • Viridian Therapeutics, Inc.\DE's 5-year Other Accumulated Expenses high stood at $228,000 for Q3 2016, and its period low was $83,000 during Q2 2016.
  • Over the past 2 years, Viridian Therapeutics, Inc.\DE's median Other Accumulated Expenses value was $143,500 (recorded in 2018), while the average stood at $143,500.
  • Data for Viridian Therapeutics, Inc.\DE's Other Accumulated Expenses shows a peak YoY increase of 125.74% (in 2016) and a maximum YoY decrease of 15.31% (in 2016) over the last 5 years.
  • Viridian Therapeutics, Inc.\DE's Other Accumulated Expenses (Quarterly) stood at $103,000 in 2015, then spiked by 43.69% to $148,000 in 2016, then reached $174,000 in 2018, then reached $113,000 in 2019.
  • Its Other Accumulated Expenses was $113,000 in Q1 2019, compared to $174,000 in Q4 2018 and $148,000 in Q4 2016.